Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Early Phase 1 Interventional

Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine

ClinicalTrials.gov ID: NCT02546752

Public ClinicalTrials.gov record NCT02546752. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This primary goal of this study is to assess whether patient whose parents watch a standardized digital video using the integrated digital approach during a routine office visit are more likely to accept a dose of HPV vaccine (1st, 2nd, or 3rd dose) compared to those not completing the program. The study team anticipates eligible patients in the intervention clinics to have higher rates of HPV vaccine acceptance (1st, 2nd, or 3rd doses) than patients in the usual care comparison clinics. Additionally, the study team is interested in determining the impact of the integrated system on clinical workflow by measuring the number of minutes of each patient office visit when using the system compared to the number of minutes of each visit in offices where the system is not used. Although this is a descriptive/exploratory aim, our expectation is that the THEO system will have minimal impact on patient flow.

Study identification

NCT ID
NCT02546752
Recruitment status
Completed
Study type
Interventional
Phase
Early Phase 1
Enrollment
1,306 participants

Conditions and interventions

Eligibility (public fields only)

Age range
11 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2015
Primary completion
Apr 30, 2016
Completion
Apr 30, 2016
Last update posted
May 24, 2016

2015 – 2016

United States locations

U.S. sites
5
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Eskenazi Health Outpatient Care Center Indianapolis Indiana 46202
Eskenazi Health Center Blackburn Indianapolis Indiana 46208
Eskenazi Health Center Forest Manor Indianapolis Indiana 46226
Eskenazi Health West 38th Street Indianapolis Indiana 46254
Eskenazi Health Pecar Indianapolis Indiana 46268

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02546752, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 24, 2016 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02546752 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →